iopofosine i 131
·Code: CLR 131
iopofosine i 131: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Cellectar Biosciences, Inc. (CLRB) | Phase 1 |
FDA Decisions
FDA_MeetingEMA SAWP advised that filing for a Conditional Marketing Authorization for iopofosine I 131 in post-BTKi refractory Waldenstrom macroglobulinemia could be acceptable and met eligibility requirements.(CLRB)
Frequently asked questions
Who is developing iopofosine i 131?
iopofosine i 131 is being developed by Cellectar Biosciences, Inc..
What is iopofosine i 131's latest FDA decision?
The most recent tracked FDA decision for iopofosine i 131 is FDA_Meeting for EMA SAWP advised that filing for a Conditional Marketing Authorization for iopofosine I 131 in post-BTKi refractory Waldenstrom macroglobulinemia could be acceptable and met eligibility requirements..
Get deeper analysis on iopofosine i 131
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis